Literature DB >> 14707107

Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus.

Insoo Kang1, Timothy Quan, Helena Nolasco, Sung-Hwan Park, Myung Sun Hong, Jill Crouch, Eric G Pamer, John Greg Howe, Joe Craft.   

Abstract

EBV infection is more common in patients with systemic lupus erythematosus (SLE) than in control subjects, suggesting that this virus plays an etiologic role in disease and/or that patients with lupus have impaired EBV-specific immune responses. In the current report we assessed immune responsiveness to EBV in patients with SLE and healthy controls, determining virus-specific T cell responses and EBV viral loads using whole blood recall assays, HLA-A2 tetramers, and real-time quantitative PCR. Patients with SLE had an approximately 40-fold increase in EBV viral loads compared with controls, a finding not explained by disease activity or immunosuppressive medications. The frequency of EBV-specific CD69+ CD4+ T cells producing IFN-gamma was higher in patients with SLE than in controls. By contrast, the frequency of EBV-specific CD69+ CD8+ T cells producing IFN-gamma in patients with SLE appeared lower than that in healthy controls, although this difference was not statistically significant. These findings suggest a role for CD4+ T cells in controlling, and a possible defect in CD8+ T cells in regulating, increased viral loads in lupus. These ideas were supported by correlations between viral loads and EBV-specific T cell responses in lupus patients. EBV viral loads were inversely correlated with the frequency of EBV-specific CD69+ CD4+ T cells producing IFN-gamma and were positively correlated with the frequencies of CD69+ CD8+ T cells producing IFN-gamma and with EBV-specific, HLA-A2 tetramer-positive CD8+ T cells. These results demonstrate that patients with SLE have defective control of latent EBV infection that probably stems from altered T cell responses against EBV.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14707107     DOI: 10.4049/jimmunol.172.2.1287

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  84 in total

Review 1.  Immune modulation during latent herpesvirus infection.

Authors:  Douglas W White; R Suzanne Beard; Erik S Barton
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

2.  Latent virus infection upregulates CD40 expression facilitating enhanced autoimmunity in a model of multiple sclerosis.

Authors:  Costanza Casiraghi; Ana Citlali Márquez; Iryna Shanina; Marc Steven Horwitz
Journal:  Sci Rep       Date:  2015-09-10       Impact factor: 4.379

3.  Selective Loss of Signaling Lymphocytic Activation Molecule Family Member 4-Positive CD8+ T Cells Contributes to the Decreased Cytotoxic Cell Activity in Systemic Lupus Erythematosus.

Authors:  Katalin Kis-Toth; Denis Comte; Maria P Karampetsou; Vasileios C Kyttaris; Lakshmi Kannan; Cox Terhorst; George C Tsokos
Journal:  Arthritis Rheumatol       Date:  2016-01       Impact factor: 10.995

4.  Everyone comes from somewhere: systemic lupus erythematosus and Epstein-Barr virus induction of host interferon and humoral anti-Epstein-Barr nuclear antigen 1 immunity.

Authors:  John B Harley; Judith A James
Journal:  Arthritis Rheum       Date:  2010-06

5.  Epstein-Barr virus promotes interferon-alpha production by plasmacytoid dendritic cells.

Authors:  Timothy E Quan; Robert M Roman; Benjamin J Rudenga; V Michael Holers; Joseph E Craft
Journal:  Arthritis Rheum       Date:  2010-06

Review 6.  Complement receptors and the shaping of the natural antibody repertoire.

Authors:  V Michael Holers
Journal:  Springer Semin Immunopathol       Date:  2004-12-22

Review 7.  New insights into the pathogenesis of systemic lupus erythematosus.

Authors:  Vasileios C Kyttaris; Christina G Katsiari; Yuang-Taung Juang; George C Tsokos
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

Review 8.  Epstein-barr virus: environmental trigger of multiple sclerosis?

Authors:  Jan D Lünemann; Thomas Kamradt; Roland Martin; Christian Münz
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

Review 9.  Genetics, environment, and gene-environment interactions in the development of systemic rheumatic diseases.

Authors:  Jeffrey A Sparks; Karen H Costenbader
Journal:  Rheum Dis Clin North Am       Date:  2014-09-02       Impact factor: 2.670

10.  Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies.

Authors:  Simona Cernea; Kevan C Herold
Journal:  Clin Immunol       Date:  2010-02       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.